Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Benefits include improved exercise performance and potential weight loss support
In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02
Semsarian, C
Gradients in bone morphogenetic protein-related gene expression across the growth plate
VESPER-1 VESPER-1 was a 28-week randomized, double-blind, placebo-controlled trial that assessed the efficacy and safety of once-weekly berobenatide across a range of dose levels (0.4 to 1.2 mg) in adults with obesity or overweight with hypertension and/or dyslipidemia
Real talk: no skincare ingredient works the same for everyone, and being informed helps you make better decisions for your skin
